Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan

Takeshi Arashiro, Yuzo Arima, Jin Kuramochi, Hirokazu Muraoka, Akihiro Sato, Kumi Chubachi, Atsushi Yanai, Hiroko Arioka, Yuki Uehara, Genei Ihara, Yasuyuki Kato, Naoki Yanagisawa, Akihiro Ueda, Hideaki Kato, Hideaki Oka, Yusuke Nishida, Yuki Nidaira, Takahiro Asami, Torahiko Jinta, Akira NakamuraKunihiro Oba, Daisuke Taniyama, Kei Yamamoto, Katsushi Tanaka, Kankuro Ueshima, Tetsuji Fuwa, Ashley Stucky, Tadaki Suzuki, Chris Smith, Martin Hibberd, Koya Ariyoshi, Motoi Suzuki

研究成果: ジャーナルへの寄稿学術論文査読

9 被引用数 (Scopus)

抄録

In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined).

本文言語英語
論文番号ofad240
ジャーナルOpen Forum Infectious Diseases
10
6
DOI
出版ステータス出版済み - 01-06-2023

All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 感染症

フィンガープリント

「Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル